Gilead Adjusts Planned Change in its Patient Assistance After HIV Community Pushes Back

NASTAD and others in the HIV community said they raised their concerns with Gilead about its planned change to its patient assistance program, and the company appears to have listened. | Source: Shutterstock

Drug manufacturer Gilead has altered a planned change to its patient assistance program (PAP) for uninsured people living with HIV that would have been unworkable for some vulnerable patients, HIV/AIDS caregivers and activists say. The change also would have deprived

Read More »

HHS Asks Court to Toss Out Hospitals’ 340B Contract Pharmacy Lawsuit

The lawsuit against HHS by 340B hospitals is just one of several underway over drug manufacturers’ denials of 340B pricing on drugs dispensed by contract pharmacies. | Source: Shutterstock

Outgoing U.S. Health and Human Services (HHS) Secretary Alex Azar last week asked a federal district judge to dismiss a lawsuit against him and his department by 340B hospitals over HHS’s enforcement of its 340B contract pharmacy requirements for drug

Read More »

Senate Finance Report Might Shed Light on Insulin Manufacturers’ 340B Contract Pharmacy Actions

HHS has for the second time delayed the effective date of a Trump administration rule to require health centers to provide insulin and injectable epinephrine to low-income patients at the price the centers pay for those drugs under the 340B program. The new date is July 20. | Shutterstock

U.S. insulin manufacturer and pharmacy benefit manager (PBM) business practices “have created a vicious cycle of price increases that have sent costs for patients and taxpayers through the roof,” U.S. Senate Finance Committee leaders Chuck Grassley (R-Iowa) and Ron Wyden

Read More »

340B Stakeholders Reconsider Campaign Contributions in Wake of Capitol Riot

Businesses and groups involved in 340B are reconsidering their political donations following a pro-Trump mob's assault on the U.S. Capitol. | Source: Shutterstock

National health care organizations and businesses with major stakes in the 340B program have suspended political contributions following a pro-Trump mob’s Jan. 6 violent attack on Congress to stop it from counting and certifying the Electoral College’s votes for president.

Read More »

Health Centers File 340B Dispute Resolution Petitions Against Drug Manufacturers

The National Association of Community Health Centers (NACHC) last night on its members’ behalf asked a new federal 340B program administrative dispute resolution (ADR) panel to order drug manufacturers Eli Lilly and Co., Sanofi, and AstraZeneca to lift all “qualifications,

Read More »

Lilly Asks Court to Shield it From “Crippling” 340B Sanctions

Drug manufacturer Eli Lilly and Co. told a court this week that HHS has placed it in the "untenable position of offering 340B discounts that are not required by the statute or else facing crippling financial sanctions." | Source: Shutterstock

340B program stakeholders are still digesting drug manufacturers AstraZeneca, Eli Lilly and Co., and Sanofi’s Jan. 12 lawsuits to block federal sanctions over their decisions to stop or impose conditions on 340B discounts on drugs dispensed by contract pharmacies.

Read More »

AstraZeneca, Lilly, and Sanofi Sue HHS to Block Requirement To Give 340B Discounts To Contract Pharmacies

AstraZeneca, Eli Lilly and Co., and Sanofi sued HHS in defense of their 340B contract actions just hours before covered entities could begin challenging those actions in a new 340B administrative dispute resolution process. | Source: Shutterstock

In a major escalation of the fight over 340B contract pharmacy, drug manufacturer AstraZeneca late yesterday asked a federal court to declare that it “is not required to offer 340B discounts to contract pharmacies.”

As we went to press, we

Read More »

340B Providers Blindsided by Bausch Health’s Decision to Drop AmerisourceBergen as Distributor

340B covered entities are scrambling to respond to the fallout from Bausch Health's surprise announcement that it ended its relationship with AmerisourceBergen to distribute its 340B-priced branded products. | Source: Shutterstock

Drug manufacturer Bausch Health blindsided 340B covered entities on New Year’s Eve, announcing that starting the very next day, Jan. 1, more than 200 of its branded products and future branded products would no longer be available through distributor AmerisourceBergen

Read More »

Senate Democratic Chairs-in-Waiting Waste No Time Going to Bat for 340B Providers

The incoming Democratic chairs of two key U.S. Senate committees want the federal agency in charge of the 340B program “to take immediate action to clarify that implementation of a rebate model by [drug] manufacturers would violate a material condition

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live